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Introduction. A substantial proportion of cancer patients continue to smoke after their diagnosis but few studies have evaluated
correlates of nicotine dependence and smoking rate in this population, which could help guide smoking cessation interventions.
Aim. This study evaluated correlates of smoking rate and nicotine dependence among 207 cancer patients. Methods. A cross-
sectional analysis using multiple linear regression evaluated disease, demographic, affective, and tobacco-seeking correlates of
smoking rate and nicotine dependence. Smoking rate was assessed using a timeline follow-back method. The Fagerstro¨m Test for
NicotineDependencemeasured levels of nicotine dependence.Results. Amultiple linear regression predicting nicotine dependence
showed an association with smoking to alleviate a sense of addiction from the Reasons for Smoking scale and tobacco-seeking
behavior from the concurrent choice task (𝑝 < .05), but not with affect measured by the HADS and PANAS (𝑝 > .05). Multiple
linear regression predicting prequit showed an association with smoking to alleviate addiction (𝑝 < .05). ANOVA showed that
Caucasian participants reported greater rates of smoking compared to other races. Conclusions. The results suggest that behavioral
smoking cessation interventions that focus on helping patients tomanage tobacco-seeking behavior, rather thanmoodmanagement
interventions, could help cancer patients quit smoking.
1. Introduction
TheUS Surgeon General concluded that a causal relationship
exists between continued tobacco use among cancer patients
and poor clinical outcomes, including cancer-specific mor-
tality, an increased risk of disease recurrence, and decreased
response to cancer treatment [1]. Despite these risks, upwards
of 50% of those who were smokers when diagnosed continue
to smoke or relapse soon after receiving their diagnosis
[2, 3]. Identifying effective smoking cessation interventions
for cancer patients is therefore a priority [4]. This requires
identifying correlates of smoking behavior, which can serve
as intervention targets [2].
There has been little consistency in linking disease-related
characteristics (e.g., cancer type, stage) and demographic
variables (e.g., sex, race) to cancer patient smoking rate
[5]. Some studies have found that medical variables (cancer
site and cancer type), and certain demographic variables
[1, 6], are related to smoking rate and smoking cessation
among cancer patients [7]. But other studies have failed to
demonstrate a relationship between disease-related charac-
teristics, demographic variables, and cancer patient smoking
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rate [8]. In addition, negative affect [9–11] and nicotine
withdrawal and craving [12, 13] have been associated with
a greater smoking frequency or smoking relapse in this
population. This literature provides little consensus as to
the key predictors of smoking frequency and dependence
in cancer patients, which the current study will address by
examining a range of possible predictors.
Recently, Hogarth and colleagues validated a concurrent
choice task as an index of the relative reward value that
individuals ascribe to tobacco. In this task, participants make
forced choices (over successive trials) between a response that
produces tobacco and a response that produced food. In the
general population, preferential choice of tobacco over food is
associated with smoking frequency, dependence severity, and
subject craving and can bemodulated by smoking abstinence,
smoking satiety, nicotine replacement medication, negative
mood induction, and smoking related stimuli [14–20]. The
current study tested whether smoking frequency and tobacco
dependence severity in cancer patients would be associated
with greater relative reward value ascribed to tobacco in
the concurrent choice task. This finding would suggest that
smoking in cancer patients is an economic decision driven
by the greater relative value of tobacco.
A better understanding of key correlates of smoking
and dependence in cancer patients could guide intervention
development. Given that negative affect has been reliably
associated with smoking in cancer patients [10, 11], we
expect to replicate this association here. We also expect
to demonstrate a novel association between tobacco choice
and smoking/dependence in cancer patients. These findings
would suggest that smoking cessation interventions for can-
cer patients should integrate mood management with treat-
ment strategies derived from economic decision theory [21].
2. Methods
2.1. Participants. This study, which represents secondary
analyses, utilized data from aNational Cancer Institute (NCI)
smoking cessation clinical trial (i.e., a parent trial; clini-
caltrials.gov: NCT01756885) comparing 12 versus 24 weeks
of varenicline and behavioral counseling. Participants were
recruited from cancer centers in Philadelphia and Chicago
using proactive recruitment within the electronic medical
record (EMR) and clinician referrals. To be eligible, for the
parent trial and for this study, participants had to be ≥18
years old, have a cancer diagnosis within the past 5 years,
report smoking ≥ 5 cigarettes/week, be interested in quitting
(assessed using self-reported response to “Are you interested
in quitting smoking?” during phone screen), and have a
Karnofsky score (functional capacity) > 50 or an Eastern
Cooperative Oncology Group (ECOG) performance status
(disease progression)≤ 2. All participants were either actively
in medical treatment for a cancer diagnosis or in follow-up
for a diagnosis within the past 5 years, which is consistent
with definitions of cancer patients when the trial began
recruitment. Exclusions for this study, which were the same
as those for the parent trial, can be found in a previous
study [22]. Following telephone initial eligibility screening,
participants were invited to an in-person intake session to
determine final eligibility. Of the 569 participants eligible at
phone screen, 282 were eligible at intake and 75 refused to
participate, leaving a sample of 207 participants (recruitment
rate = 73.4%). Among eligible participants who declined to
enroll, the primary reasons given for refusal were lack of
interest in the study, time commitment, and reluctance to
take the study medication. No significant differences were
found between those who chose to participate and those who
declined participation in terms of demographic, smoking
related, and disease characteristics. All participants who
attended their intake session received $10 for travel, plus an
additional $10 for time, if the entire session was completed
successfully.
2.2. Procedures. Written informed consentwas obtained at an
intake session and those eligible were randomized to 12 or 24
weeks of varenicline, with 5 counseling sessions. Data from
the present analyses were taken from participants prior to
completing their first counseling session and initiating treat-
ment. This included assessment of smoking using timeline
follow-back, questionnaires, and a computer-based, concur-
rent choice task that measured tobacco-seeking behavior.
2.3. Measures
2.3.1. Demographics, Disease Characteristics, and Smoking.
Participants self-reported demographics and smoking rate
and completed the Fagerstro¨m Test for Nicotine Dependence
(FTND) [23]. Disease characteristics (e.g., tumor site) were
ascertained from the EMR.
2.3.2. Affect. The Positive and Negative Affect Schedule
[24] assessed positive (e.g., enthusiastic) and negative (e.g.,
distressed) affect.TheHospital Anxiety and Depression Scale
[25] assessed depression and anxiety symptoms.The Reasons
for Smoking (RFS) scale assessed motivations for smoking
(i.e., smoking to reduce negative affect, provide stimulation,
or alleviate addiction) [26].
2.3.3. Withdrawal and Craving. The Shiffman-Jarvik With-
drawal Scale (SJWS) assessed nicotine withdrawal (i.e.,
craving, stimulation/sedation, psychological symptoms, and
appetite) [27]. The Brief Questionnaire of Smoking Urges
(QSU-b) [28] assessed craving. Five of the items measured
the desire to smoke for reward (Factor 1) and the other five
measured the need to smoke for negative affect relief (Factor
2). The sum of items 1–10 forms the QSU-b total.
2.3.4. Concurrent Choice Task. This computer-based task
assessed preferential tobacco versus food choice [14]. Partic-
ipants pressed the left or right key to produce an image of
smoking versus chocolate, respectively (the response-reward
contingencies were counterbalanced between subjects). This
measure is an analogue of animal choice models [29] and
simplifies earlier human tobacco choice procedures [30].
Outcomes were percent tobacco versus chocolate choice to
index the relative tobacco value and overall reaction time of
choices as a crude index of cognitive function.
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2.4. Data Analysis. The characteristics of the sample, includ-
ing demographic, disease-related, and smoking data, were
summarized using descriptive statistics (e.g., means, standard
deviations). Univariate statistics (Pearson correlation and
ANOVA) were used to examine if variables in Table 1
were associated with smoking rate (self-reported number of
cigarettes in the past 7 days) and FTND. Variables associated
with smoking rate or FTND (𝑝 < .05) from these analyses
were included in separate multiple linear regression models
in order to focus on them as distinct measures of smoking
behavior. Predictors of smoking rate and FTND within
models were evaluated using 95% confidence intervals and
probability values. Predictors were simultaneously entered
into respective linear regression models and categorical
variables were dummy coded. These procedures are similar
to those used in past studies [10].
3. Results
3.1. Sample Characteristics. Participant characteristics are
listed in Table 1. More than half of the sample was female,
more than a third were from ethnic/racial minority groups,
and close to two-thirds did not have a college degree. Close
to one-fifth of the sample had head and neck or lung cancer
and ∼60% had undergone medical treatment in the past 30
days.Overall, participants averaged smoking 15 cigarettes/day
for >40 years. Average pack year was calculated for the
population by multiplying the number of packs smoked per
day by the number of years of smoking.The average pack year
for the sample population was 30.70 (SD = 20.60).
3.2. Univariate Correlates of Smoking Rate and FTND. Table 2
outlines the Pearson correlations between demographic,
medical, and smoking variables listed in Table 1. A higher
smoking rate was associated with smoking to alleviate addic-
tion (𝑟= .36,𝑝 < .001), physical symptoms (𝑟= .266,𝑝 < .001),
and nonphysiological symptoms (𝑟= .18,𝑝 < .05) and provide
stimulation (𝑟 = .19, 𝑝 < .01), on the RFS. A higher level of
nicotine dependence was associated with higher withdrawal
on the SJWS (𝑟 = .29, 𝑝 < .001) and craving on the QSU-b (𝑟
= .32, 𝑝 < .001), including both QSU-B subscales measuring
smoking urges associated with pleasure (Factor 1) (𝑟 = .40,
𝑝 < .001) and reducing negative affect (Factor 2) (𝑟 = .25, 𝑝 <
.001). On the RFS, higher levels of nicotine dependence were
associated with smoking to alleviate negative affect (𝑟 = .23,
𝑝 ≤ .001), addiction (𝑟 = .40, 𝑝 < .001), and physiological
symptoms (𝑟 = .40, 𝑝 < .001) as well as nonphysiological
symptoms (𝑟 = .27, 𝑝 < .001) and for stimulation (𝑟 = .34,
𝑝 < .001). Higher nicotine dependence was associated with
a preference for tobacco on the choice task (𝑟 = .28, 𝑝 <
.05). Caucasians and participants with tumors other than
lung or head and neck reported a higher smoking rate when
compared to patients of racial minority groups and patients
with lung or head and neck cancer (𝐹[1, 202] = 16.26, 𝑝 <
.001; 𝐹[1, 201] = 4.66, 𝑝 = .032, resp.). Participants who
were unemployed had higher levels of nicotine dependence
compared to those who were employed (𝐹[1, 201] = 5.77, 𝑝 =
.017). Study site was not associated with outcomes.
Table 1: Characteristics of program enrollees (𝑁 = 207).
Characteristic Enrollees
𝑁 (%) or mean (SD)
Demographic variables
Gender
Male 102 (49.3)
Female 105 (50.7)
Education∗
Below college grad 132 (63.8)
College grad or beyond 73 (35.3)
Marital status
Not married 102 (49.3)
Married 103 (49.8)
Employment status∗
Employed 100 (48.3)
Not employed 105 (50.7)
Income∗
<20,000 44 (21.3)
20,000 to 75,000 91 (44)
75,000< 69 (33.3)
Race
Caucasian 142 (68.6)
Non-Caucasian 65 (31.4)
Age 58.5 (9.4)
Medical variables
Tumor site∗
Head and neck or lung 39 (18.8)
Other sites 167 (80.7)
Tumor stage
Stages 0–2 41 (19.8)
Stages 3-4 45 (21.7)
Remission/stage not specified 121 (58.5)
Time from diagnosis to intake (days)∗ 102.7 (19.6)
Cancer treatment in last month∗
Radiation 21 (10.1)
Chemotherapy 42 (20.3)
Surgery 25 (12.1)
Hormone therapy 22 (10.6)
Radiation and chemotherapy 12 (5.8)
Chemotherapy and hormone therapy 5 (2.4)
Smoking variables
Age smoking was started 16.7 (5.1)
Pack years 30.70 (20.60)
QSU-b⋀
Factor 1 16.7 (8.56)
Factor 2 8.05 (5.16)
Total 27.46 (14.01)
SJWS
Craving 15.69 (7.45)
Physical 4.36 (2.16)
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Table 1: Continued.
Characteristic Enrollees
𝑁 (%) or mean (SD)
Stimulation 2.14 (1.53)
Psychological 11.75 (4.29)
Appetite 1.99 (1.55)
RFS
Addiction 4.58 (2.16)
Stimulation 4.68 (3.11)
Negative affect 5.03 (2.47)
Physiological 8.25 (4.20)
Not physiological 6.02 (3.03)
Number of cigarettes smoked 7 days prior
to PQ∗ 75.81 (49.19)
FTND score∗ 4.5 (2.1)
Concurrent choice task (% of choice
tobacco versus chocolate)∗ 27.99 (27.12)
Affective variables
PANAS
Positive affect 35.51 (7.82)
Negative affect 13.72 (4.28)
HADS
Anxiety 4.05 (2.82)
Depression 2.45 (2.44)
Note. ∗ indicates missing data (<5%); QSU-b: Brief Questionnaire of
Smoking Urges; ⋀ = see measures for description of Factors 1 and 2; SJWS
= Shiffman-Jarvik Withdrawal Scale; RFS = Reasons for Smoking; PQ =
prequit visit; FTND = Fagerstro¨m Test for Nicotine Dependence; PANAS =
the Positive andNegative Affect Schedule; HADS = the Hospital Anxiety and
Depression Scale.
3.3. Multivariate Correlates of Smoking Rate and FTND.
Table 3 shows the results of a multivariate linear regression
for smoking rate. Caucasians reported a higher smoking
rate. Smoking to alleviate addiction was also associated with
higher smoking rates. Table 4 shows the results of a multiple
linear regression for severity of nicotine dependence. Smok-
ing to alleviate addiction and a preference for tobacco on the
choice task were associated with a higher level of nicotine
dependence.
4. Discussion
This study analyzed demographic, disease, affective, and
tobacco-seeking correlates of smoking rate and nicotine
dependence among cancer patients to identify potential
targets for smoking cessation interventions. This study is the
first to employ a novel concurrent choice task, designed to
measure tobacco-seeking behavior, with cancer patients. Our
results suggest that nicotine dependence in cancer patients
is associated with smoking to alleviate a sense of addiction
and with the greater relative value of tobacco over natural
rewards indexed by the choice task. These findings suggest
that treatments for cancer patientsmight focus on developing
coping skills for addiction or on increasing engagement
with nonsmoking rewards through contingencymanagement
or behavioral activation. The lack of association between
nicotine dependence and smoking to alleviate negative affect
suggests that mood management treatments may be less
effective.
In the final models, only race and cancer site were
correlated with smoking behavior. The association between
race and smoking rate is consistent with studies in the gen-
eral population that show African Americans, Asian/Pacific
Islanders, and Hispanic/Latinos to be more likely to be light
smokers, versus Caucasian smokers [31]. As such, in the
oncologic context, it may be necessary to consider the liter-
ature on smoking cessation interventions across light versus
heavy smokers to identify the most suitable interventions for
racial/ethnic minority groups. Contrary to previous findings
with cancer patients [9–11], affective measures were not asso-
ciated with smoking behavior, although this may be related
to patients with psychiatric comorbidity not enrolling in the
trial. In contrast, the RFS subscale focused on alleviating
addiction was associated with smoking rate and nicotine
dependence, and the concurrent choice task was associated
with dependence. Consistent with recent models of tobacco
dependence [32], these results suggest treatments for cancer
patients should focus on training skills that counteract the
belief that smoking helps cope with adverse states [33] and
focus on increasing the relative value of nonsmoking rewards
through contingency management or behavioral activation
[21].
This study is limited by the use of cross-sectional data
and participants enrolled in a clinical trial. Further, while the
results indicate that smoking behavior among cancer patients
is related to coping with sense of addiction and greater
value ascribed to tobacco, rather than demographic, disease-
related, or affective factors, these results may not be unique
to cancer patients compared to the general population.
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Table 3: Multiple regression analysis predicting number of cigarettes smoked one week before prequit visit.
Predictor variable 𝐵 𝑡 𝑝 95% CI
RFS
Addiction .342 3.64 <.001 3.28 to 11.05
Stimulation −.062 −.673 .50 −3.60 to 1.77
Cancer site −.117 −1.62 .11 −31.0 to 3.09
Race −.187 −2.49 .014 −32.92 to −3.81
Note. Model for cigarettes smoked before prequit visit: 𝐹(5, 155) = 8.1; 𝑝 < .001; RFS = Reasons for Smoking; SJWS = Shiffman-Jarvik Withdrawal Scale.
Table 4: Multiple regression analysis predicting scores on Fagerstro¨m Test for Nicotine Dependence.
Predictor variable 𝐵 𝑡 𝑝 95% CI
Employment .14 1.85 .07 −.383 to 4.02
Income −.01 −.07 .95 −.495 to .463
Age smoking was started −.09 −1.24 .22 −.112 to .026
RFS
Negative affect −.12 −1.24 .22 −.265 to .060
Addiction .36 3.68 <.001 .165 to .548
Stimulation .10 1.02 .31 −.066 to .207
QSU-b
Factor 1 .17 1.24 .22 −.025 to .111
Factor 2 −.01 −.15 .88 −.084 to .072
SJWS craving −.01 −.07 .94 −.075 to .070
% of choice (tobacco versus chocolate) .16 2.05 .04 .000 to .025
Note. Model for level of nicotine dependence: 𝐹(10, 147) = 6.39; 𝑝 < .001; RFS = Reasons for Smoking; QSU-b = Brief Questionnaire of Smoking Urges; SJWS
= Shiffman-Jarvik Withdrawal Scale.
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